Malcolm Purdy, MD
Medical Oncology · Albuquerque, NMNPI 1679535827
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,081, 2.3 times the $475 reported in 2019.
Across 159 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$390
- Novartis$361
- E.r. Squibb & Sons, L.L.C.$272
- Pfizer$153
- AstraZeneca$137
- Bayer$126
- plus $2K from 33 others
Across 6 payments — averaging $660.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$4K
What the payments were for
- Food & beverage$2,96396%
- Education$1364%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 23 | $390 |
| Novartis | 17 | $361 |
| E.r. Squibb & Sons, L.L.C. | 16 | $272 |
| Pfizer | 10 | $153 |
| AstraZeneca | 7 | $137 |
| Bayer | 6 | $126 |
| Seagen Inc. | 4 | $125 |
| Puma Biotechnology, Inc. | 6 | $109 |
| Sanofi | 5 | $104 |
| AbbVie | 5 | $103 |
| Genentech USA, Inc. | 6 | $98 |
| Array Biopharma Inc | 4 | $91 |
| Merck | 6 | $91 |
| Incyte Corporation | 4 | $86 |
| Bristol Myers Squibb | 3 | $83 |
| Johnson & Johnson | 3 | $75 |
| Astellas Pharma US Inc | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Exelixis Inc. | 3 | $50 |
| Eisai Inc. | 2 | $45 |
| Boehringer Ingelheim | 2 | $42 |
| Stemline Therapeutics Inc. | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| GSK | 2 | $32 |
| Taiho Oncology, Inc. | 2 | $32 |
| Sobi, Inc | 1 | $32 |
| EMD Serono, Inc. | 1 | $31 |
| Caris MPI, Inc. | 1 | $30 |
| Tempus AI, Inc | 1 | $26 |
| Agios Pharmaceuticals, Inc. | 1 | $25 |
| AVEO Pharmaceuticals, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Genmab U.S., Inc. | 1 | $22 |
| Beigene USA, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| X4 Pharmaceuticals, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Verastem, Inc. | 1 | $14 |
How this compares
Too few medical oncology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 56 | $917,389 |
| TagrissoOsimertinib Mesylate | 26 | $514,508 |
| ErivedgeVismodegib | 16 | $211,724 |
| Abiraterone Acetate | 41 | $92,649 |
| EliquisApixaban | 81 | $70,272 |
| XareltoRivaroxaban | 43 | $41,872 |
| Enoxaparin Sodium | 13 | $3,568 |
| Exemestane | 28 | $3,392 |
| Bicalutamide | 66 | $2,017 |
| Anastrozole | 118 | $1,918 |
| Tamoxifen Citrate | 42 | $1,013 |
| Gabapentin | 71 | $934 |
| Letrozole | 28 | $850 |
| Hydroxyurea | 23 | $730 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $83 | $917,38956 claims |
| AstraZenecaTagrisso | $137 | $514,50826 claims |
| Genentech USA, Inc.Erivedge | $98 | $211,72416 claims |
| PfizerEliquis | $153 | $70,27281 claims |
| Johnson & JohnsonXarelto | $75 | $41,87243 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.
Other medical oncology in Albuquerque
- Annette FontaineAlbuquerque$208K
- Katherine SanchezAlbuquerque$26K
- Atul KumarAlbuquerque$9K
- Sofia Palacio CardenasAlbuquerque$5K
- Amyn AlidinaAlbuquerque$2K
- Ronald KubicaAlbuquerque$1K
- Joseph EkofoAlbuquerque$195
- Colbert ParkerAlbuquerque$103
- Richard GiudiceAlbuquerque$0
- Wadih ArapAlbuquerque$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.